Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. BioVie's annualizedGross Profit for the quarter that ended in Dec. 2023 was $0.00 Mil.
BioVie's average Total Assets over the quarter that ended in Dec. 2023 was $22.63 Mil. Therefore, BioVie's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.
BioVie Gross-Profit-to-Asset % Historical Data
The historical data trend for BioVie's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioVie's Gross-Profit-to-Asset %
For the Biotechnology subindustry, BioVie's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioVie's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioVie's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where BioVie's Gross-Profit-to-Asset % falls into.
BioVie Gross-Profit-to-Asset % Calculation
BioVie's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Dec. 2023) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
BioVie Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of BioVie's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
BioVie Inc is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BIVI has been successfully added to your 